Simplifying antiretroviral therapy

AIDS Reviews

Volumn 2, Issue 2, 2000, Pages 93-98

  Nunez, M ^a   Barreiro, P ^a   Soriano, V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Non nucleosides; Simplification

Indexed keywords

ABACAVIR; HYDROXYUREA; MYCOPHENOLIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; PATIENT COMPLIANCE; REVIEW; VIRUS LOAD;

EID: 0033944034     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Antiretroviral therapy in adults. Updated recommendations of the IAS-USA Panel
2. Insights into the reasons for discontinuation of the first HAART regimen in a cohort of antiretroviral naive patients
3. Adverse drug reactions in patients with HIV infection. A prospective study
4. Heterogeneity in the response to antiretroviral therapy
5. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
6. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy
7. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients
8. MIRO: A randomized trial of maintenance therapy with or without protease inhibitors after 4 months of triple or quadruple induction therapy
9. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
10. Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy
11. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
13. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
14. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
15. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy
16. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy
17. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
18. Viral dynamics in human immunodeficiency virus type 1 infection
19. Decay characteristics of HIV-1 infected compartments during combination therapy
20. Impact of highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients
21. Latency and reservoirs for HIV-1
22. Sexual transmission and propagation of SIV and HIV-1 in activated and quiescent T cells
23. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less
24. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
25. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy
26. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
27. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
28. Induction-Maintenance (5→3 drugs) in HIV-infected patients with high viral load
29. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
30. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome on therapy
31. What dual protease inhibitor combination for salvage therapies?
32. Multiple-dose pharmacokinetics and tolerability of indinavir and ritonavir combinations in healthy volunteers
33. Ritonavir intensification in indinavir recipients with detectable HIV RNA levels
34. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
35. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
36. Epidemiological and clinical aspects of the metabolic complications of HIV infection. The fat redistribution syndrome
37. A multicentre, randomized, open-label, comparative trial of the clinical, immunological and virological benefit of switching the PI by nevirapine in HAART-experienced patients suffering lipodystrophy
38. Simplified maintenance therapy with abacavir + lamivudine/zidovudine in patients with long-term suppression of HIV RNA
39. Maintenance of viral suppression but incomplete resolution of metabolic and clinical lipid abnormalities in persons switched from protease inhibitor (PI) based to efavirenz (EFV) based therapy
40. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
41. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
42. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
43. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection
44. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)
45. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
46. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication
47. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleotide triphosphate pools
48. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
49. Immunology taught by viruses
50. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy
51. Randomized trial of continued indinavir (IDV)/AZT/3TC vs. switch to IDV/ddl/d4T or IDV/ddl/d4T + hydroxyurea in patients with viral suppression
52. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity